CD44: A key player in breast cancer

Indian Journal of Cancer

Volumn 51, Issue 3, 2014, Pages 247-250

  Anand, M T ^a   Kumar, S ^a  

^a INTERNATIONAL INSTITUTE OF INFORMATION TECHNOLOGY   (India)

Author keywords

Breast cancer; breast cancer stem cells; CD44; hyluronan

Indexed keywords

BIVATUZUMAB MERTANSINE; CD44V ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

BONE MARROW METASTASIS; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; LIVER METASTASIS; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN TARGETING; TUMOR GROWTH; TUMOR INVASION;

EID: 84920092186     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.146752     Document Type: Conference Paper

References (57)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 2005;6:391-401.
2. Huang GC HS, Walton M, Epstein RJ. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 2002;86:1104-9.
3. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-7.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.
5. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-9.
6. Hansis C, Grifo JA, Krey LC. Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. Mol Hum Reprod 2000;6:999-1004.
7. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 2002;12:432-8.
8. Kim RJ, Nam JS. OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 2011;27:147-52.
9. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res 2008;68:6281-91.
10. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, et al. A CD44 (-)/CD24 (+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2011; Nov 27. [Epub ahead of print]
11. Afify A, Pang L, Howell L. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids. Appl Immunohistochem Mol Morphol 2007;15:446-50.
12. Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin Chim Acta 2007;384:69-74.
13. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998;33:107-16.
14. Lu XQ, Suo Z, Ma CL, Xu KJ, Liu YS, Li H. [Quantity and distribution of CD44+/CD24-cells in breast cancer tissue and the cell lines]. Zhonghua Bing Li Xue Za Zhi 2009;38:441-4.
15. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6 (+)/CD24-breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest 2009;89:857-66.
16. Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol 2008;16:121-7.
17. Saleh F, Reno W. Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44. Neoplasma 2008;55:246-55.
18. Pozdnyakova O, Hoang MM, Dresser KA, Mahalingam M. Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. Arch Pathol Lab Med 2009;133:1285-90.
19. Afify A, Lynne LC, Howell L. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions. Diagn Cytopathol 2007;35:105-10.
20. Fujiwara M, Horiguchi M, Mori S, Yokoyama K, Horiguchi H, Fukazawa M, et al. Histiocytoid breast carcinoma: Solid variant of invasive lobular carcinoma with decreased expression of both E-cadherin and CD44 epithelial variant. Pathol Int 2005;55:353-9.
21. Looi LM, Cheah PL, Zhao W, Ng MH, Yip CH. CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. Malays J Pathol 2006;28:83-6.
22. Mayer S, zur Hausen A, Watermann DO, Stamm S, Jager M, Gitsch G, et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 2008;134:1229-35.
23. Watanabe O, Kinoshita J, Shimizu T, Imamura H, Hirano A, Okabe T, et al. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 2005;24:75-82.
24. Lian ZQ, Yang MT, Hou JH, Luo RZ, Wang X, Tang J. [Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma]. Ai Zheng 2006;25:1291-5.
25. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON, et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 2009;8:1436-49.
26. Kuo YC, Su CH, Liu CY, Chen TH, Chen CP, Wang HS. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int J Cancer 2009;124:2568-76.
27. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS. CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol 2007;31:1119-26.
28. Wang HS, Hung Y, Su CH, Peng ST, Guo YJ, Lai MC, et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Exp Cell Res 2005;304:116-26.
29. Thanakit V, Sampatanukul P, Ruangvejvorachai P, Keelawat S. The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. J Med Assoc Thai 2005;88 Suppl 4:S30-5.
30. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol 2007;171:2033-9.
31. Huot ME, Vogel G, Richard S. Identification of a Sam68 ribonucleoprotein complex regulated by epidermal growth factor. J Biol Chem 2009;284:31903-13.
32. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64:5702-11.
33. Celebiler Cavusoglu A, Kilic Y, Saydam S, Canda T, Baskan Z, Sevinc AI, et al. Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. Cancer Sci 2009;100:2341-5.
34. Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, et al. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone. Chin Med J (Engl) 2008;121:1980-6.
35. Mine S, Fujisaki T, Kawahara C, Tabata T, Iida T, Yasuda M, et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res 2003;288:189-97.
36. Bohn OL, Nasir I, Brufsky A, Tseng GC, Bhargava R, MacManus K, et al. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol 2009;3:139-46.
37. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. CD44 interaction with Na+-H+exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004;279:26991-7007.
38. Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009;86:95-100.
39. Zen K, Liu DQ, Guo YL, Wang C, Shan J, Fang M, et al. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS One 2008;3:e1826.
40. Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, Lower EE, et al. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol 2002;10:34-9.
41. Tanaka H, Nakamura M, Kameda C, Kubo M, Sato N, Kuroki S, et al. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res 2009;29:2147-57.
42. Lu ZH, Jia J, Ren J, Ma B, Di LJ, Song GH. [Detection of breast cancer stem cells and the expression of key molecules in Hedgehog signaling pathway]. Beijing Da Xue Xue Bao 2008;40:480-5.
43. Li X, Ren J. [Isolation of CD44+/CD24-/low and side population cells from MDA-MB-453 cells and the analysis of their activation of Wnt and Notch pathway]. Beijing Da Xue Xue Bao 2008;40:471-5.
44. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73.
45. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+cells. Oncogene 2010;29:6294-300.
46. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C (epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009;284:26533-46.
47. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 2009;284:2657-71.
48. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
49. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005;280:20310-5.
50. Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 2011;19:33-40.
51. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun 2009;9:4.
52. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009;100:918-22.
53. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009;17:153-61.
54. Wu F, Wang ZB, Cao YD, Chen WZ, Zou JZ, Bai J, et al. Changes in biologic characteristics of breast cancer treated with high-intensity focused ultrasound. Ultrasound Med Biol 2003;29:1487-92.
55. Galanzha EI, Kim JW, Zharov VP. Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in vivo detection and killing of circulating cancer stem cells. J Biophotonics 2009;2:725-35.
56. Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: Final results of a phase I study. Anticancer Drugs 2007;18:477-85.
57. Hyung W, Ko H, Park J, Lim E, Park SB, Park YJ, et al. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol Bioeng 2008;99:442-54.